NL-OMON29031已完成不适用
‘DURVIT’: Single low-dose DURValumab IntraTumorally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
Academic Medical Center (AMC)0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age > 18 years at time of study entry
- •Willing and able to undergo the planned study procedures
排除标准
- •Prior treatment with immunotherapy including therapeutic vaccines
- •Involvement in the planning and/or conduct of the study
研究者
相似试验
已完成
不适用
'DURVIT': Single low-dose DURValumab IntraTumorally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.cervix canceruterine cervical cancer1003859410013364NL-OMON50047Academisch Medisch Centrum15
进行中（未招募）
1 期
Preoperative durvlumab treatment for patients with early small triple negative breast cancerEUCTR2020-006106-23-FRGustave Roussy200
终止
1 期
Cetuximab immunotherapy combination in head and neck cancerCancerISRCTN89314418The Christie NHS Foundation Trust36
招募中
不适用
Phase II, single-arm study of durvalumab (MEDI4736) and AZD 6738 combination therapy in relapsed small cell lung cancer SubjectsKCT0005058Samsung Medical Center45
进行中（未招募）
1 期
Study of advacned resectable head and neck cancer with immunotherapy and radiotherapy before surgeryAdvanced resectable head and neck tumorMedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001641-40-ITISTITUTI FISIOTERAPICI OSPITALIERI14